NCT01841736 2026-04-13
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT01217931 2026-01-30
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01931098 2025-08-11
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
NCT07087158 2025-07-28
A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 2 Not yet recruiting
NCT05679921 2025-07-16
Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma
Yonsei University
Phase 2 Recruiting